Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

FENS 2020 | Tackling gaps in research for dementia

Tara Spires-Jones • 16 Jul 2020
FENS 2020
Alzheimer’s Disease Dementia

Tara Spires-Jones, PhD, University of Edinburgh, Edinburgh, UK, discusses the main challenges in the field of dementia research, including making the link between genetic risks and brain changes, understanding selective vulnerability, clinical trials design and funding. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Tara Spires-Jones

Gene-environment interactions and neurodegeneration
1:48
Gene-environment interactions and neurodegeneration
Tara Spires-Jones • 16 Jul 2020
Alzheimer's disease pathogenesis: more than neurons and synapses
0:57
Alzheimer's disease pathogenesis: more than neurons and synapses
Tara Spires-Jones • 16 Jul 2020
Cellular interactions in Alzheimer’s disease pathogenesis
2:30
Cellular interactions in Alzheimer’s disease pathogenesis
Tara Spires-Jones • 16 Jul 2020
Potential therapeutic strategies for Alzheimer's disease: neuron-glia interactions
1:29
Potential therapeutic strategies for Alzheimer's disease: neuron-glia interactions
Tara Spires-Jones • 16 Jul 2020

Related Videos

PCSK9-targeted therapies and the risk of stroke and dementia: a meta-analysis of RCTs
3:34
PCSK9-targeted therapies and the risk of stroke and dementia: a meta-analysis of RCTs
Vikash Jaiswal • 26 Aug 2026
How AI and data science are advancing obstructive sleep apnea management
2:23
How AI and data science are advancing obstructive sleep apnea management
Omonigho Michael Bubu • 15 Jun 2026
Obstructive sleep apnea and Alzheimer's disease risk: toward personalized care
5:40
Obstructive sleep apnea and Alzheimer's disease risk: toward personalized care
Omonigho Michael Bubu • 15 Jun 2026
Clinical markers of progression in prodromal alpha-synucleinopathies
1:28
Clinical markers of progression in prodromal alpha-synucleinopathies
Dario Arnaldi • 28 Jun 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals